Composite Endpoints: Proceed with Caution - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Composite Endpoints: Proceed with Caution The use of composite endpoints are being regarded as a useful strategy, but caution must be applied as there are both risks and benefits.

Source: Applied Clinical Trials


The choice of a valid primary endpoint is crucial for a randomized controlled trial (RCT) designed to demonstrate efficacy of a new pharmaceutical drug. Recent improvements in medical management, however, have led to a continuous decline in mortality and morbidity for several common disorders, i.e., also in the incidence of clinically relevant outcomes that may be addressed in a drug trial as an endpoint. For example, secondary prevention after myocardial infarction with aspirin, β-blockers, ACE inhibitors, and statins has remarkably lowered the rate of a subsequent cardiovascular event,1 and combination antiretroviral therapy for HIV infection has made mortality even unfeasible as a clinical endpoint.2



Moreover, for many diseases a standard of care has been established, and it is often not possible anymore to compare new therapeutic options with no treatment or placebo for ethical reasons.3,4 As a consequence, the effect sizes observed with add-on treatments when compared to standard treatment are generally lower today. Both the reduced incidence of disease-related events and the limited chance to provide significant differences in treatment effects require trials with large sample sizes.5

As a solution to maintain feasibility of RCTs, particularly those facing low event rates, the investigation of composite endpoints has been introduced and become fashionable in the last few years.

Why to use a composite endpoint

A composite endpoint in a RCT consists of multiple single endpoints that are combined in order to confront an investigational drug with a higher number of events expected during the trial. For instance, the primary composite endpoint may include mortality along with nonfatal endpoints such as hospitalization and cardiac arrest in chronic heart failure patients,6 or along with myocardial infarction and stroke in hypertensives.7

The major advantages in using a composite endpoint are: statistical precision and efficiency will be increased8 ; trials become smaller, less costly; and the results of promising new treatments will be available earlier. If more than one outcome is important for efficacy evaluation, a composite endpoint can efficiently deal with the issue of multiplicity.9 A summary measure for drug efficacy can be defined10 (e.g., the assessment of skeletal-related events [SREs] in trials for prevention or treatment of bone metastases).

The selection of composite endpoints has been regarded as "a useful strategy" for registration of pharmaceuticals in the ICH E9 guideline.9 A Points-to-consider document released by the European Agency for the Evaluation of Medicinal Products (EMEA) specifies regulatory requirements.11

Clinical and regulatory requirements

The use of a composite endpoint in a clinical trial is usually justified if the following assumptions are respected:

  • The individual components of the composite are clinically meaningful and of similar importance to the patient.8
  • The expected effects on each component are similar, based on biological plausibility12 (which is, in the end, the rationale for using a composite endpoint). Accordingly, regulatory guidelines also require components for which it can be assumed treatment will beneficially influence in a similar way.
  • The clinically more important components of composite endpoints should at least not be affected negatively.11

As a consequence of the third assumption, regulatory authorities require all components of a composite endpoint to be analyzed separately.9,11 One needs to be aware whether a treatment affects all components or just a single outcome.5


ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here